The Biology and Clinical Uses of Blood Stem Cells

To, LB; Haylock, DN; Simmons, P. J.; Juttner, CA

doi:10.1182/blood.v89.7.2233

Cited by 629 publications

(290 citation statements)

References 187 publications

Supporting

Mentioning

274

Contrasting

Unclassified

Order By: Relevance

“…G-CSF administration leads to a relative increase of the number of myeloid precursor cells in human bone marrow and blood (28) and a relative decrease of the B cell precursors (28,29). Similar results are obtained with SCF (7). IL-7 enhances proliferation and differentiation of B-lymphoid precursors (3).…”

Section: Discussionmentioning

confidence: 66%

See 1 more Smart Citation

Growth factor receptor profile of CD34⁺ cells in AML and B‐lineage ALL and in their normal bone marrow counterparts

Waele¹,

Renmans²,

Gucht³

et al. 2001

European J of Haematology

View full text Add to dashboard Cite

Leukaemic cells show a low clonogenic activity and a heterogeneous proliferative response to growth factors. We investigated whether this could be due to an altered expression of growth factor receptors on the leukaemic precursors. Receptors for G-CSF, stem cell factor (SCF), IL-3, IL-6 and IL-7 were detected on CD34+ cells in AML and B-lineage ALL with monoclonal antibodies and flow cytometry. The expression was compared with that on myeloid and B-lymphoid CD34+ cells in normal bone marrow. Leukaemic CD34+ cells expressed the same receptors as their normal counterparts. AML and B-lineage ALL could be distinguished by the growth factor receptor profile of their CD34+ cells. SCFR, G-CSFR and IL-6Ralpha were found in AML, IL-7R in B-lineage ALL and IL-3Ralpha in both. IL-3Ralpha was upregulated in AML and B-lineage ALL CD34+ cells, while samples with low or high expression were present for the other receptors. This variable expression could correlate with the heterogeneous response of leukaemic cells to growth factors. Functional studies on isolated CD34+ cells are needed to investigate this further.

show abstract

Section: Discussionmentioning

confidence: 66%

“…Interleukin-7 (IL-7) has been shown to induce proliferation of B-cell precursors (5) and is critical for T cell development (6). Some of these growth factors also mobilize precursor cells towards the blood (7). The large majority of these lymphohaemopoietic precursors are characterized by the expression of the CD34 antigen (8).…”

mentioning

confidence: 99%

Growth factor receptor profile of CD34⁺ cells in AML and B‐lineage ALL and in their normal bone marrow counterparts

Waele¹,

Renmans²,

Gucht³

et al. 2001

European J of Haematology

View full text Add to dashboard Cite

show abstract

“…BM cells were identified by immunostaining with anti-GFP antibody (Medical and Biological Laboratories. CO., Nagoya, Japan) as described previously (14).…”

Section: Bone Marrow Transplantationmentioning

confidence: 99%

Cytokine therapy prevents left ventricular remodeling and dysfunction after myocardial infarction through neovascularization

Ohtsuka¹,

Takano²,

Zou³

et al. 2004

FASEB j.

182

138

View full text Add to dashboard Cite

Pretreatment with a combination of granulocyte colony-stimulating factor (G-CSF) and stem cell factor (SCF) has been reported to attenuate left ventricular (LV) remodeling after acute myocardial infarction (MI). We here examined whether the cytokine treatment started after MI has also beneficial effects. Anterior MI was created in the recipient mice whose bone marrow had been replaced with that of transgenic mice expressing enhanced green fluorescent protein (GFP). We categorized mice into five groups according to the following treatment: 1) saline; 2) administration of G-CSF and SCF from 5 days before MI through 3 days after; 3) administration of G-CSF and SCF for 5 days after MI; 4) administration of G-CSF alone for 5 days after MI; 5) administration of SCF alone for 5 days after MI. All the three treatment groups with G-CSF showed less LV remodeling and improved cardiac function and survival rate after MI. The number of capillaries, which express GFP, was increased and the number of apoptotic cells was decreased in the border area of all the treatment groups with G-CSF. Even if the cytokine treatment is started after MI, it could prevent LV remodeling and dysfunction after MI--at least in part--through an increase in neovascularization and a decrease in apoptosis in the border area.

show abstract

“…PBSC transplantation has advantages: easy collection and enrichment of CD34 þ cells; increased cost effectiveness; and lower risk for contamination with tumor cells in comparison to conventional bone marrow cell transplantation. (54)(55)(56)(57)(58) Therefore, we combined PBSC transplantation with mechanical support and designed this randomized clinical trial to sufficiently validate the efficiency of the combination treatment in comparison with biomechanical support alone. Because PBSC transplantation can promote new bone ingrowth into the tantalum rod and dead bone repair by stimulating and guiding bone remodeling, the combination treatment obtained a better effect in the treatment of ONFH than biomechanical support alone.…”

Section: Discussionmentioning

confidence: 99%

Combination Treatment of Biomechanical Support and Targeted Intra-arterial Infusion of Peripheral Blood Stem Cells Mobilized by Granulocyte-Colony Stimulating Factor for the Osteonecrosis of the Femoral Head: A Randomized Controlled Clinical Trial

Mao

Wang

et al. 2014

Journal of Bone and Mineral Research

View full text Add to dashboard Cite

Objective To determine the benefits of combination treatment with mechanical support and targeted intra-arterial infusion of peripheral blood stem cells (PBSCs) mobilized by granulocyte-colony stimulating factor (G-CSF) via the medial circumflex femoral artery on the progression of osteonecrosis of the femoral head (ONFH). Methods 55 patients (89 hips) with early and intermediate stage ONFH were recruited and randomly assigned to combination treatment or mechanical support treatment (control group). All hips received mechanical support treatment (porous tantalum rod implantation). Then, Hips in the combination treatment group were performed targeted intra-arterial infusion of PBSCs. At each follow-up, Harris hip score (HHS) and Association Research Circulation Osseous classification (ARCO) were used to evaluate the symptoms and progression of osteonecrosis. Total hip arthroplasty (THA) was assessed as an endpoint at each follow-up. Results At 36 months, 9 of the 41 hips (21.95%) in the control group progressed to clinical failure and underwent THA whereas only 3 of the 48 hips (6.25%) in the combination treatment group required THA(p=0.031). Kaplan-Meier survival analysis showed a significant difference in the survival time between the two groups (Log-rank test; p=0.025). Compared to the control group, combination treatment significantly improved the HHS at 36 months (p=0.003). At the final follow-up examination, radiological progression was noted in 13 of 41 hips (31.71%) for the control group, while only in 4 of 48 hips (8.33%) for the combination treatment group (p=0.005). The overall collapse rates were 15.15% (5 of 33 hips) and 8.11% (3 of 37 hips) in the control and combination treatment groups, respectively. Conclusions Targeted intra-arterial infusion of PBSCs is capable of enhancing the efficacy of biomechanical support in the treatment of ONFH. This clinical trial confirmed that the combination treatment might be a safe and feasible choice for the treatment of early or intermediate stages of ONFH.

show abstract

The Biology and Clinical Uses of Blood Stem Cells

Cited by 629 publications

References 187 publications

Growth factor receptor profile of CD34⁺ cells in AML and B‐lineage ALL and in their normal bone marrow counterparts

Growth factor receptor profile of CD34⁺ cells in AML and B‐lineage ALL and in their normal bone marrow counterparts

Cytokine therapy prevents left ventricular remodeling and dysfunction after myocardial infarction through neovascularization

Combination Treatment of Biomechanical Support and Targeted Intra-arterial Infusion of Peripheral Blood Stem Cells Mobilized by Granulocyte-Colony Stimulating Factor for the Osteonecrosis of the Femoral Head: A Randomized Controlled Clinical Trial

Contact Info

Product

Resources

About

The Biology and Clinical Uses of Blood Stem Cells

Cited by 629 publications

References 187 publications

Growth factor receptor profile of CD34+ cells in AML and B‐lineage ALL and in their normal bone marrow counterparts

Growth factor receptor profile of CD34+ cells in AML and B‐lineage ALL and in their normal bone marrow counterparts

Cytokine therapy prevents left ventricular remodeling and dysfunction after myocardial infarction through neovascularization

Combination Treatment of Biomechanical Support and Targeted Intra-arterial Infusion of Peripheral Blood Stem Cells Mobilized by Granulocyte-Colony Stimulating Factor for the Osteonecrosis of the Femoral Head: A Randomized Controlled Clinical Trial

Contact Info

Product

Resources

About

Growth factor receptor profile of CD34⁺ cells in AML and B‐lineage ALL and in their normal bone marrow counterparts

Growth factor receptor profile of CD34⁺ cells in AML and B‐lineage ALL and in their normal bone marrow counterparts